Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

By J. Wilmott, Georgina V. Long, J. Howle, L. Haydu, Raghwa N. Sharma, John F. Thompson, R. Kefford, P. Hersey, R. Scolyer. Clinical Cancer Research, 2011

631 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/9767a296a73c78f19a444a3b86347894a3807f57

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Guido Kroemer
2. L. Galluzzi
3. Oliver Kepp
4. L. Zitvogel
5. M. Smyth
6. Douglas R. Green
7. Beth Levine
8. Simone Fulda

In Oncology

1. Guido Kroemer
2. L. Galluzzi
3. L. Zitvogel
4. Oliver Kepp
5. M. Smyth
6. Rebecca S. Y. Wong

Citations in the corpus

• Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. (2013, background): “Activation of T Cells The BRAF inhibitors GSK2118436 and vemurafenib increase the infiltration of humanmelanomasbyCD4+ andCD8+granzyme-Bexpressing ab T cells, correlating with a reduction in tumor size (Wilmott et al., 2012).”
• Targeted agents and immunotherapies: optimizing outcomes in melanoma (2017, neutral): “ 89) OS Dacarbazine (208) 0% 100% 35.6% 41.8% 61% 13.9% 2.2 mo 8% 10.8 mo 41% NR Nivolumab (210) 0% 100% 37.6% 29.1% 61% 40% 5.1 mo 44% Not reached 73% NR METRIC53 PFS Chemotherapy (108) 100% 65% 39% 36% 58% 8% 1.5 mo NR NR NR NR Trametinib (214) 100% 67% 36% 36% 67% 22% 4.8 mo NR NR NR NR COMBI-d‡ ”
• Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. (2015, background): “…et al., 2011 GSK2118436 melanoma favors tumor infiltration by CD4+ cells and CTLs correlates with reduction in tumor size and degree of necrosis Wilmott et al., 2012 Ibrutinib transplantable murine lymphoma promotes ICD in combination with intratumoral injection of a TLR9 agonist Sagiv-Barfi…”